Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie S Callander

Showing results (41-50 of 95) with videos related to

Pageof 10
Sort By:
Gynecologic Oncology|July 21, 2004
Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group studyPatrick J Stiff, Elizabeth J Shpall, P Y Liu, et al.
Blood|January 27, 2026
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapySusan Bal, Gayathri Ravi, Binod Dhakal, et al.
Transplantation and Cellular Therapy|January 20, 2024
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) TrialEhsan Malek, Jeries Kort, Leland Metheny, et al.
The Journal of Biological Chemistry|December 28, 2017
Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myelomaMailee Huynh, Chorom Pak, Stephanie Markovina, et al.
Science Advances|March 24, 2023
Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathologyNicholas J Hess, David P Turicek, Jeremiah Riendeau, et al.
Scientific Reports|June 23, 2022
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ modelEvan Flietner, Zhi Wen, Adhithi Rajagopalan, et al.
Oncogene|April 8, 2023
Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responsesEvan Flietner, Mei Yu, Govinda Poudel, et al.
British Journal of Haematology|September 10, 2011
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03Susanna J Jacobus, Shaji Kumar, Hajime Uno, et al.
British Journal of Haematology|February 16, 2026
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplantPriyanka Venkatesh, Gayathri Ravi, Binod Dhakal, et al.
Acta Haematologica|July 24, 2019
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)Sanford Kempin, Zhuoxin Sun, Neil E Kay, et al.
Pageof 10

Showing results (41-50 of 95) with videos related to

Sort By:
Pageof 10
Gynecologic Oncology|July 21, 2004
Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group studyPatrick J Stiff, Elizabeth J Shpall, P Y Liu, et al.
Blood|January 27, 2026
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapySusan Bal, Gayathri Ravi, Binod Dhakal, et al.
Transplantation and Cellular Therapy|January 20, 2024
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) TrialEhsan Malek, Jeries Kort, Leland Metheny, et al.
The Journal of Biological Chemistry|December 28, 2017
Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myelomaMailee Huynh, Chorom Pak, Stephanie Markovina, et al.
Science Advances|March 24, 2023
Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathologyNicholas J Hess, David P Turicek, Jeremiah Riendeau, et al.
Scientific Reports|June 23, 2022
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ modelEvan Flietner, Zhi Wen, Adhithi Rajagopalan, et al.
Oncogene|April 8, 2023
Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responsesEvan Flietner, Mei Yu, Govinda Poudel, et al.
British Journal of Haematology|September 10, 2011
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03Susanna J Jacobus, Shaji Kumar, Hajime Uno, et al.
British Journal of Haematology|February 16, 2026
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplantPriyanka Venkatesh, Gayathri Ravi, Binod Dhakal, et al.
Acta Haematologica|July 24, 2019
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)Sanford Kempin, Zhuoxin Sun, Neil E Kay, et al.
Pageof 10